The presence of shock or respiratory failure did not prolong D2B times in patients using the Rampart system. The Rampart ...

Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...

Use of beta-blockers has been a cornerstone in the treatment era following acute myocardial infarction (MI), especially in ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Background Prehospital delays remain critical barriers to timely acute coronary syndrome (ACS) care, particularly for ...

The Ministry of Health on January 12 conducted a medical services drill at the National Convention Centre to ensure health ...

The annual report covers the five most impactful cardiovascular diseases, aiming for accountability and action.

Participating experts underscored that smooth communication and close coordination among medical forces are a decisive factor ...

Drs Harrington and Gibson’s annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

The Department of Medical Service Administration under the Ministry of Health convened a meeting in Hanoi on January 10 to ...

Preliminary but promising.Those three words emerged as a recurring theme in conversations about several abstracts presented at this year’s ASH Annual Meeting and Exposition that examined the effects ...